Review of the Development of DNA Methylation as a Marker of Response to Neoadjuvant Therapy and Outcomes in Rectal Cancer

Clinical Epigenetics - Germany
doi 10.1186/s13148-015-0111-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Metabolic Nodal Response as a Prognostic Marker After Neoadjuvant Therapy for Oesophageal Cancer

British Journal of Surgery
Surgery
2017English

MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response After Neoadjuvant Therapy

Radiology
Nuclear MedicineRadiologyImaging
2018English

Establishment of a DNA Methylation Marker to Evaluate Cancer Cell Fraction in Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2015English

DNA Sequence Context as a Marker of CpG Methylation Instability in Normal and Cancer Tissues

Scientific Reports
Multidisciplinary
2020English

Lack of Pathological Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy Is Associated With Poorer Long-Term Oncological Outcomes

Clinical Oncology and Research
2019English

Pretreatment Serum Cea as a Predictive Biomarker for the Response to Neoadjuvant Chemoradiotherapy: A Meta-Analysis in Rectal Cancer

Journal of Carcinogenesis & Mutagenesis
2015English

Promoter Methylation of TRIM9 as a Marker for Detection of Circulating Tumor DNA in Breast Cancer Patients

SpringerPlus
Multidisciplinary
2015English

MRI‑based Neoadjuvant Therapy Indication in Middle and Low Rectal Cancer

Bratislava Medical Journal
2019English

Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II-III Across European Countries: Variations and Outcomes

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy